Full-Time

Cybersecurity Quality Engineer

Updated on 9/3/2026

Masimo

Masimo

1,001-5,000 employees

Noninvasive patient monitoring devices and wearables

Compensation Overview

$85k - $105k/yr

+ Bonus

Irvine, CA, USA

In Person

Domestic and international travel up to 20–25% may be required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Threat modeling
Vulnerability Analysis

Get referred to Masimo

See people who can refer or advise you

Requirements
  • Bachelor’s degree in Computer Engineering, Computer Science, Electrical Engineering, Biomedical Engineering, Software Engineering, or related technical discipline
  • 0–3 years of experience in quality engineering, software quality, cybersecurity, product security, or related engineering field; relevant internship, co-op, or project-based experience in regulated environments will be considered
  • Foundational understanding of cybersecurity concepts including vulnerability management, threat modeling, software security, network security, and secure development principles
  • Familiarity with quality systems, design controls, software lifecycle documentation, or regulated engineering processes
  • Strong attention to detail and ability to manage documentation accurately
  • Effective written and verbal communication skills
  • Ability to manage multiple tasks and priorities in a dynamic, cross-functional environment
Responsibilities
  • Support execution of cybersecurity quality activities across assigned product development programs, including documentation review, milestone tracking, and quality record maintenance
  • Assist in the preparation, review, and maintenance of cybersecurity-related design control documentation, including threat modeling records, vulnerability assessments, security risk analyses, cybersecurity protocols, and test reports
  • Maintain traceability between cybersecurity requirements, software design outputs, mitigation activities, and verification/validation records within the Design History File (DHF)
  • Support authoring, review, and periodic updates of cybersecurity-related quality system procedures, work instructions, templates, and documentation standards
  • Assist in cybersecurity vulnerability monitoring and post-market surveillance activities, including tracking disclosed vulnerabilities, supporting impact assessments, and documenting remediation activities
  • Support management of cybersecurity-related nonconformances, CAPAs, deviations, and engineering changes through the quality management system, ensuring accurate documentation and timely follow-up
  • Participate in cross-functional design reviews, cybersecurity risk reviews, and project meetings, supporting quality representation for cybersecurity-related topics
  • Collaborate with R&D, Software Engineering, Regulatory Affairs, Product Security, and Quality teams to support consistent application of cybersecurity quality requirements across development activities
  • Support preparation of cybersecurity documentation required for audits, regulatory submissions, inspections, and internal quality reviews
  • Assist in evaluation of third-party software components, open-source software dependencies, and Software Bill of Materials (SBOM) documentation to support cybersecurity traceability and risk awareness
  • Support internal audits, readiness activities, and documentation reviews related to cybersecurity quality and design control compliance
  • Stay current with evolving regulatory guidance, industry standards, and cybersecurity best practices relevant to medical device development
Desired Qualifications
  • Exposure to medical device, healthcare technology, embedded systems, or regulated software environments
  • Familiarity with FDA 21 CFR Part 820, ISO 13485, ISO 14971, FDA cybersecurity guidance, or related regulatory expectations
  • Awareness of standards such as AAMI TIR57, IEC 62304, IEC 81001-5-1, or NIST cybersecurity frameworks
  • Exposure to Software Bill of Materials (SBOM), software traceability, or software quality documentation practices
  • Foundational knowledge of software validation, software quality assurance, or secure SDLC practices
  • Security+, ISC2 CC, or similar entry-level cybersecurity certification is a plus

Masimo is a global medical technology company that develops, manufactures, and markets noninvasive patient monitoring technologies for the healthcare sector. Its core offerings include the Root patient monitoring and connectivity platform and the Masimo W1 health-tracking wearable with FDA-cleared modules, reflecting a focus on noninvasive monitoring and consumer health wearables. The company expanded into consumer electronics by acquiring Sound United, enabling products that deliver personalized, lossless sound alongside health data capabilities. Its goal is to improve life by enhancing patient monitoring and delivering high-quality sound experiences, bridging healthcare with everyday health and wellness.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Neuchâtel, Switzerland

Founded

1989

Get referred to Masimo

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA cleared pediatric PSi on July 27, 2026, expanding SedLine's clinical reach.
  • FDA cleared continuous DO2 monitoring on Root with LiDCO, deepening perioperative differentiation.
  • Danaher's deal promised over $530 million EBITDA in 2027 and $125 million synergies by 2031.

What critics are saying

  • Danaher owns Masimo now; autonomy disappeared and integration decisions can cut headcount fast.
  • Apple's redesigned watch survived import-ban challenges, ending Masimo's platform leverage against consumer wearables.
  • If Danaher mishandles integration, Masimo becomes a squeezed product line inside a larger portfolio.

What makes Masimo unique

  • Masimo's SET pulse oximetry remains embedded across major U.S. hospitals and surgery workflows.
  • Root, SedLine, and LiDCO combine hemodynamics, EEG, and oxygenation into one platform.
  • Danaher kept Masimo as a standalone Diagnostics brand after June 10, 2026 acquisition.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Paid Maternity Leave

Health Savings Account/Flexible Spending Account

Flexible Work Hours

Pet Insurance

Wellness Program

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

7%
Newswise
Sep 2nd, 2026
American Society of Anesthesiologists announces 14-year collaboration with Masimo as a Corporate Supporter.

American Society of Anesthesiologists announces 14-year collaboration with Masimo as a Corporate Supporter. Newswise - CHICAGO - The American Society of Anesthesiologists (ASA) today announced the continuation of its longstanding collaboration with Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient-monitoring solutions, through ASA's Corporate Supporter Program. Now in its 14th year, the relationship supports education and initiatives designed to advance anesthesia care and help improve patient outcomes. "As an anesthesiologist, I understand the critical role that education, innovation, and reliable technology play in delivering the highest-quality patient care," said ASA President Patrick Giam, M.D., FASA. "We welcome Masimo's continued collaboration and support through the ASA Corporate Supporter Program. Working together, we will advance the specialty, provide anesthesiologists with valuable resources, and ultimately improve outcomes for the patients we serve." As a Corporate Supporter, Masimo continues to build on its longstanding relationship with the anesthesiology community, strengthen collaboration between anesthesiologists and industry, and add to the value the Society provides to members and their patients, while providing invaluable year-round support of ASA programs and priorities related to perioperative care. Corporate Supporters have unique opportunities to inform strategic dialogue with leaders in anesthesiology from around the world and during major ASA events including the ANESTHESIOLOGY(R) annual meeting and ADVANCE: The Anesthesiology Business Event. "Masimo has always believed that the best innovation starts with a deep understanding of clinicians and the patients they serve," said Tim Benner, president of Masimo. "For 14 years, our collaboration with ASA has given us an important opportunity to support the anesthesiology community through education, dialogue and shared learning. We're proud to continue that commitment as we work together to advance patient care and improve outcomes." Established in 2010, ASA's Corporate Supporter Program is limited to 10 organizations. The program recognizes leading companies that demonstrate a sustained commitment to advancing the specialty of anesthesiology through support of education, innovation, and initiatives that benefit anesthesiologists and the Anesthesia Care Team. ABOUT THE AMERICAN SOCIETY OF ANESTHESIOLOGISTS Founded in 1905, the American Society of Anesthesiologists (ASA) is an educational, research and scientific society with more than 60,000 members organized to advance the medical practice of anesthesiology and secure its future. ASA is committed to ensuring anesthesiologists evaluate and supervise the medical care of all patients before, during and after surgery. ASA members also lead the care of critically ill patients in intensive care units, as well as treat pain in both acute and chronic settings. ABOUT MASIMO Masimo, a Danaher company and a specialty diagnostics solutions innovator of pulse oximetry and other patient monitoring solutions, develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is for our innovations to empower clinicians to transform patient care. Masimo SET(R) Measure-through Motion and Low Perfusion(TM) pulse oximetry, introduced in 1995, has been shown to outperform other pulse oximetry technologies in over 100 independent and objective studies, which can be found at www.masimo.com/evidence/featured-studies/feature. Masimo SET(R) is estimated to be used on more than 200 million patients around the world each year and is the primary pulse oximetry at all 10 top U.S. hospitals as ranked in the 2026 Newsweek World's Best Hospitals listing. Additional information about Masimo and its products may be found at www.masimo.com. ABOUT DANAHER Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges - helping move innovations from discovery to delivery faster for patients who depend on them. Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow. Explore more at www.danaher.com. Media contact. Type OF article. Section.

PR Newswire
Aug 25th, 2026
Masimo gains FDA clearance for continuous oxygen delivery monitoring system

Masimo has received FDA 510(k) clearance for Root with LiDCO and the Masimo LiDCO Sensor, enabling continuous monitoring of oxygen delivery (DO₂). The device combines LiDCO hemodynamic monitoring, noninvasive haemoglobin measurement (SpHb), and Masimo SET pulse oximetry to provide beat-to-beat assessment of oxygen delivery. The technology addresses a historical limitation in DO₂ monitoring, which previously relied on intermittent laboratory measurements of haemoglobin. By integrating cardiac output, haemoglobin, and oxygen saturation into a single continuous measure, the system offers clinicians real-time visibility into oxygen transport during surgery and periods of physiological stress. Masimo, a Danaher company, develops pulse oximetry and patient monitoring solutions. The clearance expands the company's monitoring portfolio by providing an integrated view of oxygen delivery to tissue.

PR Newswire
Aug 18th, 2026
Masimo receives CE Mark for AI-powered smartSedLine brain function monitor

Masimo, a Danaher company, has received CE Mark approval for smartSedLine, its next-generation brain function monitor featuring an AI-powered Patient State Index (PSi) algorithm. The device is designed to provide more responsive monitoring during anaesthetic induction and increased stability in low-power EEG conditions, which can occur in geriatric and critically ill patients. The smartSedLine continuously processes four real-time bilateral frontal electroencephalogram waveforms, generating key parameters to help clinicians assess a patient's anaesthesia state. The PSi index ranges from 0 to 100, reflecting sedation levels. The device builds on Masimo's brain function monitoring capabilities and forms part of the company's broader Brain Health Platform. SmartSedLine PSi will be available in applicable markets and is pending 510(k) approval in the US.

TheWrap
Aug 12th, 2026
Former Disney CEO Bob Chapek writing tell-all memoir.

Former Disney CEO Bob Chapek writing tell-all memoir. "Behind the Castle Walls: My 30 Years at the Happiest Place on Earth" will cover the exec's "high-stakes maneuverings" that unraveled behind the scenes from his 2020 appointment to his subsequent dismissal in 2022 August 12, 2026 @ 2:31 PM Former Disney CEO Bob Chapek is writing a tell-all memoir about his life and career, including his three decades at the entertainment giant and the "high-stakes maneuverings that unraveled behind the scenes from his 2020 appointment to his subsequent dismissal in 2022." The book, entitled "Behind the Castle Walls: My 30 Years at the Happiest Place on Earth," will be released on Sep. 29, according to Simon & Schuster's Gallery Books, which serves as its publisher. Chapek's book is a collaboration with Don Yaeger. Chapek was elevated to the role of Disney CEO just weeks before the COVID-19 pandemic ravaged the globe, forcing closures of the company's theme parks and cruise ships and shuttering live sporting events and film and television production, leaving thousands of employees out of work. Following a number of PR debacles, including his mishandling of the situation around Florida's "Don't Say Gay" law in 2021, a lawsuit by Marvel star Scarlett Johansson early on during COVID and the sudden dismissal of respected Disney streaming and television leader Peter Rice, Chapek was ousted from Disney and his predecessor-turned-successor Bob Iger returned to the company in late 2022. "Was he really given a fair shot or was he set up to fail? What drove his ousting and Bob Iger's return? What happened behind the scenes at Disney during COVID, and how did those decisions impact what we see today?," the book's description stated. "Four years later, after reflection and healing, Chapek is ready to tell his story, sharing what he hopes will be his true legacy. Even now, after everything, he's still a lifelong fan, and wants the magic of Disney to endure for generations." Following his ouster, Chapek joined the board of directors of the medical tech firm Masimo in 2024, but ended up resigning a year later. Meanwhile, Iger has stepped down from the Disney CEO role once again, handing off the reins to Josh D'Amaro, who succeeded Chapek as head of the experiences business.

PR Newswire
Jul 27th, 2026
Masimo gets FDA clearance for first sedation score designed for children's brains

Masimo, a Danaher company, has received FDA 510(k) clearance for the Pediatric Patient State Index (PSi), the first sedation score designed specifically for children's brain physiology. The technology monitors depth of sedation in patients aged four and older during surgery and intensive care. Pediatric PSi is the only index derived from bilateral brain data and indicated for use with both propofol and sevoflurane anaesthetics. The clearance follows clinical data from 169 paediatric patients showing the algorithm's effectiveness in tracking sedation stages and detecting burst suppression, a sign of potential oversedation. Masimo SedLine, first cleared for paediatric use in 2022, monitors brain activity through electroencephalogram signals from both brain halves. The technology addresses challenges in paediatric sedation monitoring, as children's brains respond differently to anaesthesia than adults'.